PharmacoEconomics

1998 - 2012

Edited by Christopher I. Carswell, MSc, MRPharmS

from Springer Healthcare | Adis
Series data maintained by Dave Dustin ().

Access Statistics for this journal.
Track citations for all items by RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 24, issue 12, 2006

Acknowledgement pp. 1169-1171

Adis International Limited

Do Pharmacogenomic Tests Provide Value to Policy Makers? pp. 1173-1177

Ya-Chen Tina Shih and Lajos Pusztai

Letter From the Commissioner's Office at the US FDA pp. 1179

John Vernon

Assessing Generalisability in Model-Based Economic Evaluation Studies: A Structured Review in Osteoporosis pp. 1181-1197

Hege Urdahl, Andrea Manca and Mark Sculpher

Generic Health-Related Quality-of-Life Assessment in Children and Adolescents: Methodological Considerations pp. 1199-1220

Ulrike Ravens-Sieberer, Michael Erhart, Nora Wille, Ralf Wetzel, Jennifer Nickel and Monika Bullinger

Cost Effectiveness of Tumour Necrosis Factor-alpha Inhibitors as First-Line Agents in Rheumatoid Arthritis pp. 1221-1232

James Spalding and Joel Hay

Association of Co-Morbidities with Prescribing Patterns and Cost Savings: Olanzapine versus Risperidone for Schizophrenia pp. 1233-1248

Wei Yu, Xinhua Ren, Austin Lee, Lawrence Herz, Yu-Hui Huang and Lewis Kazis

Candesartan Cilexetil: A Pharmacoeconomic Review of its Use in Chronic Heart Failure and Hypertension pp. 1249-1272

Greg Plosker and Susan Keam

Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies pp. 1273-1274

Stuart Birks

The Authors' Reply pp. 1275-1276

J.M. Bos, M.J. Postma and L. Annemans

Volume 24, issue 11, 2006

Better Analysis for Better Decisions: Facing Up to the Challenges pp. 1039-1042

Michael Drummond and Mark Sculpher

Recent Developments in Decision-Analytic Modelling for Economic Evaluation pp. 1043-1053

Milton Weinstein

Using Value of Information Analysis to Prioritise Health Research: Some Lessons from Recent UK Experience pp. 1055-1068

Karl Philip Claxton and Mark Sculpher

Utility Measurement in Healthcare: The Things I Never Got To pp. 1069-1078

George Torrance

Pharmacoeconomics and Pharmacoepidemiology: Curious Bedfellows or a Match Made in Heaven? pp. 1079-1086

Andrew Briggs and Adrian Levy

Analysis Sans Frontieres: Can We Ever Make Economic Evaluations Generalisable Across Jurisdictions? pp. 1087-1099

Mark Sculpher and Michael Drummond

`Lost in Translation': Accounting for Between-Country Differences in the Analysis of Multinational Cost-Effectiveness Data pp. 1101-1119

Andrea Manca and Andrew Willan

Information Created to Evade Reality (ICER): Things We Should Not Look to for Answers pp. 1121-1131

Stephen Birch and Amiram Gafni

Economic Evaluation and Decision Making in the UK pp. 1133-1142

Martin Buxton

Building Bridges Between Academic Research and Policy Formulation: The PRUFE Framework - an Integral Part of Ontario's Evidence-Based HTPA Process pp. 1143-1156

Ron Goeree and Leslie Levin

Economic Evaluations in the Canadian Common Drug Review pp. 1157-1162

Andreas Laupacis

Economic Evaluation in the US: What is the Missing Link? pp. 1163-1168

Peter Neumann and Sean Sullivan

Volume 24, issue 10, 2006

The Generalisability of Pharmacoeconomic Studies: Issues and Challenges Ahead pp. 937-945

James Mason and Anne Rosemary Mason

QALYs: Are They Helpful to Decision Makers? pp. 947-952

Maurice McGregor and J. Jaime Caro

Should We Abandon QALYs as a Resource Allocation Tool? pp. 953-954

Sandeep Vijan

Therapeutic Options for the Prevention and Treatment of Postoperative Nausea and Vomiting: A Pharmacoeconomic Review pp. 955-970

Jean Lachaine

Single-Inhaler Combination Therapy for Asthma: A Review of Cost Effectiveness pp. 971-988

Manabu Akazawa and David Stempel

Disability and Quality of Life in Post-Traumatic Stress Disorder: Impact of Drug Treatment pp. 989-998

Soraya Seedat, Christine Lochner, Bavanisha Vythilingum and Dan Stein

Hospitalisation Costs of Cystic Fibrosis pp. 999-1009

Jonas Schreyögg, Helge Hollmeyer, Miriam Bluemel, Doris Staab and Reinhard Busse

The Initial Validation of a Markov Model for the Economic Evaluation of (New) Treatments for Rheumatoid Arthritis pp. 1011-1020

Paco Welsing, Johan Severens, Margriet Hartman, Anke van Gestel, Piet van Riel and Roland Laan

The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US pp. 1021-1033

Patrick Sullivan, Thomas Arant, Samuel Ellis and Heather Ulrich

Anticoagulation for Stroke Prevention: High Effectiveness, More Cost Benefit? pp. 1035-1038

Eduard Shantsila, Timothy Watson and Gregory Lip

Volume 24, issue 9, 2006

US FDA Guidance: Apropos of PROs pp. 833-836

Paul Kind

Accuracy versus Transparency in Pharmacoeconomic Modelling: Finding the Right Balance pp. 837-844

David Eddy

The Value of Thinly Spread QALYs pp. 845-853

Duncan Mortimer

Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework: Some Considerations pp. 855-868

Emma McIntosh

Cost-of-Illness Studies: A Review of Current Methods pp. 869-890

Ebere Akobundu, Jing Ju, Lisa Blatt and C. Daniel Mullins

Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996-2003 pp. 891-902

Yue-Chune Lee, Ming-Chin Yang, Yu-Tung Huang, Chien-Hsiang Liu and Sun-Bing Chen

Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia: Cost Effectiveness and Risk Sharing pp. 903-915

John Wlodarczyk, Leslie Cleland, Anne Keogh, Keith McNeil, Kate Perl, Robert Weintraub and Trevor Williams

Missing Data Imputation in Quality-of-Life Assessment: Imputation for WHOQOL-BREF pp. 917-925

Ting Hsiang Lin

Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes pp. 927-929

Andrew Palmer and Craig Currie

The Authors' Reply pp. 929-935

Adrian Bagust, Marc Evans, Sophie Beale, Philip Home, Andrew Perry, Murray Stewart, Arran Shearer, Alan Martin, Lisa Hulme, Andreas Liebl, Oliver Schoeffski, Anita Goertz, Javier Ampudia-Blasco, Belen Martinez-Lage, Isabel Perez Escolano and Gonzalo Paris

Volume 24, issue 8, 2006

Cost Effectiveness of Leukotriene Modifiers in Adults with Asthma pp. 727-742

Pamela Heaton

Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension: A Systematic Review of Economic Evidence pp. 743-750

Michelle Orme and Annabel Boler

A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials pp. 751-765

Darren Clayson, Diane Wild, Paul Quarterman, Isabelle Duprat-Lomon, Maria Kubin and Stephen Joel Coons

Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease pp. 767-781

Virginia Priest, Evan Begg, Sharon Gardiner, Christopher Frampton, Richard Gearry, Murray Barclay, David Clark and Paul Hansen

A Multi-Country Health Economic Evaluation of Highly Concentrated N-3 Polyunsaturated Fatty Acids in Secondary Prevention after Myocardial Infarction pp. 783-795

Mark Lamotte, Lieven Annemans, Pawel Kawalec and York Zoellner

Costs of Inflammatory Bowel Disease in Germany pp. 797-814

Renee Stark, Hans-Helmut Konig and Reiner Martin Leidl

Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada pp. 815-830

Michele Kohli, Cheryl Attard, Annette Lam, Daniel Huse, John Cook, Chantal Bourgault, Evo Alemao, Donald Yin and Michael Marentette

National-Level Purchasing of Expensive Drugs is Increasing Pressure on the Hospital Drug Budget pp. 831-832

Slobodan Jankovic and Nebojsa Milivojevic

Volume 24, issue 7, 2006

NICE Says No to Inhaled Insulin: What Lessons Should We Learn? pp. 627-629

Nick Freemantle

Economic Models of Antiretroviral Therapy: Searching for the Optimal Strategy pp. 631-642

Fred Hellinger

Developing Health-Related Quality-of-Life Instruments for Use in Asia: The Issues pp. 643-650

Yin Bun Cheung and Julian Thumboo

Cost of Lung Cancer: A Methodological Review pp. 651-659

Laurent Molinier, Christophe Combescure, Cristos Chouaid, Jean-Pierre Daures, Bruno Housset, Didier Fabre, Alain Grand and Alain Vergnenegre

Hepatitis C: Cost of Illness and Considerations for the Economic Evaluation of Antiviral Therapies pp. 661-672

John Wong

Usefulness of the Audit of Diabetes-Dependent Quality-of-Life (ADDQoL) Questionnaire in Patients with Diabetes in a Multi-Ethnic Asian Country pp. 673-682

Hwee-Lin Wee, Chee-Eng Tan, Su-Yen Goh and Shu-Chuen Li

Tapering Off Benzodiazepines in Long-Term Users: An Economic Evaluation pp. 683-694

Richard Oude Voshaar, Paul Krabbe, Wim Gorgels, Eddy Adang, Anton van Balkom, Eloy van de Lisdonk and Frans Zitman

Cost Effectiveness of Budesonide/Formoterol for Maintenance and Reliever Therapy versus Salmeterol/Fluticasone plus Salbutamol in the Treatment of Asthma pp. 695-708

Gunnar Johansson, Emma Andreasson, Per Larsson and Claus Vogelmeier

Clopidogrel: A Pharmacoeconomic Review of its Use in Patients with Non-ST Elevation Acute Coronary Syndromes pp. 709-726

Katherine Lyseng-Williamson and Greg Plosker

Volume 24, issue 6, 2006

Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy: Implications for Decision Making pp. 523-535

Cornelis Boersma, Jarir Atthobari, Ron Gansevoort, Lolkje de Jong-Van den Berg, Paul de Jong, Dick de Zeeuw, Lieven Annemans and Maarten Postma

Healthcare Rationing in Spain: Framework, Descriptive Analysis and Consequences pp. 537-548

Rosa Rodriguez-Monguio and Fernando Antonanzas Villar

The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy pp. 549-558

George Carides, Shahnaz Shahinfar, Erik Dasbach, William Keane, William Gerth, Charles Alexander, William Herman, Barry Brenner and the RENAAL Investigators

The Effects of Type 1 Diabetes and its Long-Term Complications on Physical and Mental Health Status pp. 559-569

Jarmo Hahl, Helena Hamalainen, Tuula Simell and Olli Simell

Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients: Modelling Study from the Hospital Perspective in Germany pp. 571-591

Peter Schadlich, Michael Kentsch, Manfred Weber, Wolfgang Kammerer, Josef Brecht, Vijay Nadipelli and Eduard Huppertz

Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients: A Pharmacoeconomic Analysis pp. 593-607

George Dranitsaris, Mark Vincent and Mark Crowther

Is the Childhood Asthma Questionnaire a Good Measure of Health-Related Quality of Life of Asthmatic Children in Asia?: Validation Among Paediatric Patients with Asthma in Singapore pp. 609-621

Lee-Yee Chong, Oh-Moh Chay and Li Shu-Chuen

Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer's Disease pp. 623-625

Nick Bosanquet and Andrew Yeates

The Authors' Reply pp. 625-626

Colin Green, Joanna Picot, Emma Loveman, Andrea Takeda, Jo Kirby and Andrew Clegg

Volume 24, issue 5, 2006

Accounting for Tastes: A German Perspective on the Inclusion of Patient Preferences in Healthcare pp. 419-423

Florian Vogt, David Schwappach and John Bridges

Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus: A Systematic Literature Review pp. 425-441

Sylvia Vijgen, Mirjam Hoogendoorn, Caroline Baan, G. de Wit, Wien Limburg and Talitha Feenstra

Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: Based on Data from the Medical Research Council LU19 Trial pp. 443-452

Laura Bojke, Mark Sculpher, Richard Stephens, Wendi Qian, Nick Thatcher and David Girling

Encouraging Smokers to Quit: The Cost Effectiveness of Reimbursing the Costs of Smoking Cessation Treatment pp. 453-464

Janneke Kaper, Edwin Wagena, Constant van Schayck and Johan Severens

Comprehensive Decision-Analytic Model and Bayesian Value-of-Information Analysis: Pentoxifylline in the Treatment of Chronic Venous Leg Ulcers pp. 465-478

Cynthia Iglesias and Karl Philip Claxton

Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia: Evidence from a 16-Week Randomised Trial pp. 479-494

Shelby Reed, Jasmina Radeva, Davey Daniel, Samir Mody, Jamie Forlenza, R. McKenzie and Kevin Schulman

Letrozole: A Pharmacoeconomic Review of its Use in Postmenopausal Women with Breast Cancer pp. 495-517

Christopher Dunn and Susan Keam

Cost Considerations in the Medical Management of Glaucoma in the US: Estimated Yearly Costs and Cost Effectiveness of Bimatoprost Compared with Other Medications pp. 519-520

Javier Soto

The Authors' Reply pp. 520-522

Lawrence Goldberg and John Walt

Volume 24, issue 4, 2006

Rationing of Drugs for Rare Diseases pp. 315-316

Dyfrig Hughes

Bernard S. Bloom, PhD pp. 317-318

Henry Glick

The Burden of Age-Related Macular Degeneration pp. 319-334

Jordana Schmier, Mechelle Jones and Michael Halpern

Economic and Developmental Considerations for Pharmacogenomic Technology pp. 335-343

John Vernon, Scott Johnson, W. Hughen and Antonio Trujillo

Optimal Assignment of Treatments to Health States Using a Markov Decision Model: An Introduction to Basic Concepts pp. 345-354

Mohan Bala and Josephine Mauskopf

Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment: A Review and Consolidation of Quality Assessment pp. 355-371

Zoe Philips, Laura Bojke, Mark Sculpher, Karl Philip Claxton and Su Golder

Post-Exposure Influenza Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the UK pp. 373-386

Beate Sander, Frederick Hayden, Marlene Gyldmark and Louis Garrison

A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy pp. 387-400

Aslam Anis, Huiying Sun, Sonia Singh, John Woolcott, Bohdan Nosyk and Marc Brisson

Productivity Costs in Health-State Valuations: Does Explicit Instruction Matter? pp. 401-414

Marieke Krol, Werner B.F. Brouwer and Pedram Sendi

Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women pp. 415-416

Stephanie Land

The Authors' Reply pp. 416-417

Richard Milne, Kathy Heaton-Brown, Paul Hansen, David Thomas, Vernon Harvey and Alison Cubitt

Volume 24, issue 3, 2006

Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better? pp. 211-213

Dyfrig Hughes

Aromatase Inhibitors in Breast Cancer: A Review of Cost Considerations and Cost Effectiveness pp. 215-232

Jonathan Karnon

Trends in Outpatient Prescription Drug Use and Related Costs in the US: 1998-2003 pp. 233-236

Diane Wysowski, Laura Governale and Joslyn Swann

Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy: The UK Perspective pp. 237-250

Jonathan Karnon, Thomas Delea, Stephen Johnston, Robert Smith, Jane Brandman, Jennifer Sung and Paul Goss

Cost Considerations in the Medical Management of Glaucoma in the US: Estimated Yearly Costs and Cost Effectiveness of Bimatoprost Compared with Other Medications pp. 251-264

Lawrence Goldberg and John Walt

Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer's Disease and Other Dementias pp. 265-280

Jerrold Hill, Howard Fillit, Simu Thomas and Sobin Chang

Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women pp. 281-292

Richard Milne, Kathy Heaton-Brown, Paul Hansen, David Thomas, Vernon Harvey and Alison Cubitt

Eliciting Social Preference Weights for Functional Assessment of Cancer Therapy-Lung Health States pp. 293-294

A. Pickard, Deborah Dobrez and David Cella

The Authors' Reply pp. 294-296

Paul Kind and Sue Macran

Bimatoprost: A Pharmacoeconomic Review of its Use in Open-Angle Glaucoma and Ocular Hypertension pp. 297-314

Greg Plosker and Susan Keam

Volume 24, issue 2, 2006

Better Analysis for Better Decisions: Has Pharmacoeconomics Come of Age? pp. 107-108

Michael Drummond and Mark Sculpher

Sociodemographic Differences in Quality of Life in Rheumatoid Arthritis pp. 109-121

Erik Groessl, Theodore Ganiats and Andrew Sarkin

Differential Effects of Atypical versus Typical Antipsychotic Medication on Earnings of Schizophrenia Patients: Estimates from a Prospective Naturalistic Study pp. 123-139

David Salkever, Eric Slade and Mustafa C. Karakus

Combination Vaccine Against Invasive Meningococcal B and Pneumococcal Infections: Potential Epidemiological and Economic Impact in The Netherlands pp. 141-153

Jasper Bos, Hans Rumke, Robert Welte, Lodewijk Spanjaard, Loek van Alphen and Maarten Postma

A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease pp. 155-169

Mark Lamotte, Lieven Annemans, Thomas Evers and Maria Kubin

The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia pp. 171-191

Rachael DiSantostefano, Andrea Biddle and John Lavelle

Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries: France, Italy, Germany and the UK pp. 193-205

Antoine Lafuma, Antoine Brezin, Stefania Lopatriello, Klaus Hieke, Julia Hutchinson, Viviane Mimaud and Gilles Berdeaux

How Much is the Cost of Visual Impairment: Caveat Emptor pp. 207-209

Catherine Meads and Chris Hyde

How Much is the Cost of Visual Impairment: the Author's Reply pp. 210

Antoine Lafuma

Volume 24, issue 1, 2006

Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis pp. 1-19

A.E. Ades, Mark Sculpher, Alex Sutton, Keith Abrams, Nicola Cooper, Nicky Welton and Guobing Lu

Costs of Irritable Bowel Syndrome in the UK and US pp. 21-37

Stefanie Maxion-Bergemann, Frank Thielecke, Florian Abel and Rito Bergemann

Too Important to Ignore: Informal Caregivers and Other Significant Others pp. 39-41

Werner B.F. Brouwer

Incorporating Carer Effects into Economic Evaluation pp. 43-53

Simon Dixon, Mel Walker and Sam Salek

Interstitial Cystitis: Cost, Treatment and Co-morbidities in an Employed Population pp. 55-65

Eric Wu, Howard Birnbaum, Milena Mareva, Andrew Parece, Zihong Huang, David Mallett and Haya Taitel

Evaluation of the Cost Effectiveness of Sirolimus versus Tacrolimus for Immunosuppression Following Renal Transplantation in the UK pp. 67-79

Phil McEwan, Simon Dixon, Keshwar Baboolal, Pete Conway and Craig Currie

Cost Effectiveness of Bemiparin Sodium versus Unfractionated Heparin and Oral Anticoagulants in the Acute and Long-Term Treatment of Deep Vein Thrombosis pp. 81-92

Antonio Gomez-Outes, Eduardo Rocha, Javier Martinez-Gonzalez and Vijay Kakkar

Economic Evaluation of Rivastigmine in Patients with Parkinson's Disease Dementia pp. 93-106

Andrew Willan, Ron Goeree, Eleanor Pullenayegum, Christopher McBurney and Gordon Blackhouse